aTYR PHARMA INC Revenue
aTYR PHARMA INC (ATYR) reported Revenue of $190.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-03-05
- aTYR PHARMA INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- aTYR PHARMA INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $190.00K.
- aTYR PHARMA INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00.
- aTYR PHARMA INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- aTYR PHARMA INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $190.00K, a 19.15% decline from fiscal 2024.
- aTYR PHARMA INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $235.00K, a 33.43% decline from fiscal 2023.
- aTYR PHARMA INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $353.00K, a 96.60% decline from fiscal 2022.
- aTYR PHARMA INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $10.39M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $190.00K derived: sum of 2 quarters · filed 2026-03-05 | $190.00K derived: sum of 3 quarters · filed 2026-03-05 | $190.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $190.00K 10-Q · filed 2025-11-06 | $190.00K derived: sum of 2 quarters · filed 2025-11-06 | $190.00K 10-Q · filed 2025-11-06 | $190.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $235.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $235.00K 10-Q · filed 2025-11-06 | $235.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $235.00K 10-Q · filed 2025-08-07 | $235.00K derived: sum of 3 quarters · filed 2026-03-05 | $588.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $235.00K 10-Q · filed 2025-05-07 | $235.00K derived: sum of 2 quarters · filed 2026-03-05 | $588.00K derived: sum of 3 quarters · filed 2026-03-05 | $588.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $353.00K derived: sum of 2 quarters · filed 2026-03-05 | $353.00K derived: sum of 3 quarters · filed 2026-03-05 | $353.00K 10-K · filed 2026-03-05 |
| 2023-09-30 | $353.00K 10-Q · filed 2024-11-07 | $353.00K derived: sum of 2 quarters · filed 2024-11-07 | $353.00K 10-Q · filed 2024-11-07 | $10.74M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $10.39M derived: sum of 3 quarters · filed 2025-03-13 | $10.39M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $10.39M derived: sum of 2 quarters · filed 2025-03-13 | $10.39M derived: sum of 3 quarters · filed 2025-03-13 | |
| 2022-12-31 | $10.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $10.39M derived: sum of 2 quarters · filed 2025-03-13 | $10.39M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $2.20M derived: sum of 2 quarters · filed 2023-03-14 | $2.39M derived: sum of 3 quarters · filed 2023-03-14 | $10.46M 10-K · filed 2023-03-14 |
| 2020-09-30 | $148.00K 10-Q · filed 2021-11-12 | $337.00K derived: sum of 2 quarters · filed 2021-11-12 | $8.40M 10-Q · filed 2021-11-12 | $8.55M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $189.00K 10-Q · filed 2021-08-11 | $8.25M 10-Q · filed 2021-08-11 | $8.40M derived: sum of 3 quarters · filed 2022-03-15 | $8.58M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $8.06M 10-Q · filed 2021-05-14 | $8.21M derived: sum of 2 quarters · filed 2022-03-15 | $8.39M derived: sum of 3 quarters · filed 2022-03-15 | $8.49M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $328.00K derived: sum of 2 quarters · filed 2022-03-15 | $422.00K derived: sum of 3 quarters · filed 2022-03-15 | $422.00K 10-K · filed 2022-03-15 |
| 2019-09-30 | $184.00K 10-Q · filed 2020-11-13 | $278.00K derived: sum of 2 quarters · filed 2020-11-13 | $278.00K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $94.00K 10-Q · filed 2020-08-13 | $94.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |